Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
05/1999
05/27/1999WO1999025832A1 Toso
05/27/1999WO1999025823A2 Recombinant allergen with reduced enzymatic activity
05/27/1999WO1999025734A2 Th2 CELL DEPLETION; COMPOSITIONS; METHODS
05/27/1999WO1999025718A1 5H-PYRANO[2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY
05/27/1999WO1999025714A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
05/27/1999WO1999025697A1 Novel pyridazine derivatives and drugs containing the same as the active ingredient
05/27/1999WO1999025695A1 5-arylpyrazole compounds
05/27/1999WO1999025693A1 Metalloproteinase inhibitors
05/27/1999WO1999025379A1 Modified antibodies with enhanced ability to elicit an anti-idiotype response
05/27/1999WO1999025378A1 Immunoglobulin molecules having a synthetic variable region and modified specificity
05/27/1999WO1999025377A1 Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection
05/27/1999WO1999025376A1 Bacterial vaccines comprising auxotrophic, attenuated strains of listeria expressing heterologous antigens
05/27/1999WO1999025373A1 Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
05/27/1999WO1999025372A1 Small peptides and methods for treatment of asthma and inflammation
05/27/1999WO1999025366A1 Use of cytokines and mitogens to inhibit pathological immune responses
05/27/1999WO1999025359A1 New composition of matter
05/27/1999WO1999025352A1 Combination therapy for the treatment of aids
05/27/1999WO1999025348A1 5-ht1f agonists
05/27/1999WO1999012964A3 Kay - a novel immune system protein
05/27/1999WO1999010480A3 New tissue-specific calpaines, their production and their use
05/27/1999WO1998055495A3 Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
05/27/1999WO1998049292A3 Polypeptides associated with activator receptors and their biological applications
05/27/1999CA2310269A1 Immunoglobulin molecules having a synthetic variable region and modified specificity
05/27/1999CA2310248A1 5-ht1f agonists
05/27/1999CA2309990A1 Modified antibodies with enhanced ability to elicit an anti-idiotype response
05/27/1999CA2309885A1 Recombinant allergen with reduced enzymatic activity
05/27/1999CA2309761A1 Th2 cell depletion; compositions; methods
05/27/1999CA2309343A1 Toso
05/27/1999CA2309164A1 Combination therapy for the treatment of aids
05/26/1999EP0918059A1 Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them
05/26/1999EP0917647A1 Method of determining variations in the properties of a sample
05/26/1999EP0917581A1 Fusion polypeptides com0prising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
05/26/1999EP0917572A2 Secreted proteins and polynucleotides encoding them
05/26/1999EP0917570A2 Mhc binding peptide oligomers and methods of use
05/26/1999EP0917462A1 Cell adhesion inhibitors
05/26/1999EP0804459A4 Therapeutic compound - fatty acid conjugates
05/26/1999EP0752991B1 IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONES ANTAGONISTS OF AMPA AND NMDA RECEPTORS
05/26/1999EP0678034B1 Inducing cytotoxic t lymphocyte responses
05/26/1999CN1217714A Substituted indazole derivatives and their use as inhibitors phosphodiesterase (PDE) type IV and production of tumor necrosis factor (TNF)
05/26/1999CN1217662A Water soluble paclitaxel prodrugs
05/25/1999US5907038 Azepanes
05/25/1999US5906988 Methods of treatment using ranolazine and related piperazine derivatives
05/25/1999US5906826 Adminstering a biocompabilbe solid implant having the antigen releasably contained therein during a period when maternal antiboides are circulating in a mammal and are effective to stimulate active immunity
05/25/1999US5906821 Viral nucleotide sequences
05/25/1999US5906820 Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
05/25/1999US5906816 Method for treatment of autoimmune diseases
05/25/1999CA2011452C Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7–,17–)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn -3-one
05/20/1999WO1999024836A1 125 human secreted proteins
05/20/1999WO1999024579A1 Novel era
05/20/1999WO1999024565A1 Methods and compositions for immunomodulation
05/20/1999WO1999024469A1 Secreted proteins and polynucleotides encoding them
05/20/1999WO1999024425A1 Benzimidazole derivatives and pharmaceutically acceptable salts thereof
05/20/1999WO1999024423A1 Piperidine derivatives and their use as tachykinin antagonists
05/20/1999WO1999024421A1 Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
05/20/1999WO1999024419A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/20/1999WO1999024416A1 Aminothiazole inhibitors of cyclin dependent kinases
05/20/1999WO1999024408A1 Heterocyclic compounds having mmp and tnf inhibitory activity
05/20/1999WO1999024406A1 Phenyl-alkyl-imidazoles as h3 receptor antagonists
05/20/1999WO1999024405A1 H3 receptor ligands of the phenyl-alkyl-imidazoles type
05/20/1999WO1999024404A1 Substituted pyridine compounds as anti-inflammatory agents
05/20/1999WO1999024399A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/20/1999WO1999024077A2 Compositions and methods for targeted delivery of biologically-active factors
05/20/1999WO1999024066A2 Methods and compositions for enhancing immune response and for the production of in vitro mabs
05/20/1999WO1999024039A1 Method for reducing mast cell mediated allergic reactions
05/20/1999WO1999024035A1 Benzothiazole protein tyrosine kinase inhibitors
05/20/1999WO1999024024A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
05/20/1999WO1999023867A2 Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use
05/20/1999WO1999015553A3 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
05/20/1999WO1999015503A3 Process for making diaryl pyridines useful as cox-2 inhibitors
05/20/1999WO1999011666B1 N-terminal modifications of rantes and methods of use
05/20/1999WO1999010494A3 Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
05/20/1999WO1999006557A3 Mammalian cell membrane proteins; related reagents
05/20/1999WO1998031796A8 Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
05/20/1999CA2309609A1 Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
05/20/1999CA2309319A1 Benzothiazole protein tyrosine kinase inhibitors
05/20/1999CA2309162A1 Piperidine derivatives and their use as tachykinin antagonists
05/20/1999CA2309121A1 Phenyl-alkyl-imidazoles as h3 receptor antagonists
05/20/1999CA2309007A1 Secreted proteins and polynucleotides encoding them
05/20/1999CA2308768A1 125 human secreted proteins
05/20/1999CA2308586A1 H3 receptor ligands of the phenyl-alkyl-imidazoles type
05/20/1999CA2308440A1 Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use
05/20/1999CA2308406A1 Method for reducing mast cell mediated allergic reactions
05/20/1999CA2308361A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/20/1999CA2308359A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/20/1999CA2308358A1 Heterocyclic compounds having mmp and tnf inhibitory activity
05/19/1999EP0916670A2 Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists
05/19/1999EP0916343A1 use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases
05/19/1999EP0915879A1 Novel compounds
05/19/1999EP0915704A1 Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents
05/19/1999EP0915700A1 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
05/19/1999EP0915651A1 Il-8 receptor antagonists
05/19/1999EP0772440A4 Carbon monoxide dependent guanylyl cyclase modifiers
05/19/1999EP0434747B1 RECOMBINANT VACCINES BASED ON THE gB-PROTEIN OF MAREK'S DISEASE VIRUS
05/19/1999CN1217027A Parapoxviruses contg. foreign DNA, their prodn. and their use in vacciens
05/19/1999CN1217025A Processed polypeptides with IL-16 activity, process for preparing same and their use
05/19/1999CN1217024A Chemokine alpha 2
05/19/1999CN1216994A Apoptosis inducing molecule II
05/19/1999CN1216993A Alkyl-4-silyl-phenols and esters thereof as anti-atherosclerotic agent
05/19/1999CN1216921A Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2,6-di-alkyl-4-silyl-phenols
05/19/1999CN1043405C Method for prepn. of pharmaceutical compositions contg. heterocyclic amide derivatives
1 ... 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 ... 1172